Ucb SA
XBRU:UCB

Watchlist Manager
Ucb SA Logo
Ucb SA
XBRU:UCB
Watchlist
Price: 154.35 EUR 1.78% Market Closed
Market Cap: 30B EUR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one UCB stock under the Base Case scenario is 199.22 EUR. Compared to the current market price of 154.35 EUR, Ucb SA is Undervalued by 23%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

UCB Relative Value
Base Case
199.22 EUR
Undervaluation 23%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

4.7
P/S
P/S
Price to Sales
4.7
vs History
17
vs Industry
24
Median 3Y
3
Median 5Y
3.1
Industry
2.4
Forward
4.3
More Details
27.1
P/E
P/E
Price to Earnings
27.1
vs History
46
vs Industry
14
Median 3Y
37
Median 5Y
25.6
Industry
20.3
Forward
20.3
More Details
23.2
P/OCF
P/OCF
Price to OCF
23.2
vs History
23
vs Industry
16
Median 3Y
15.9
Median 5Y
15.1
Industry
15.6
More Details
53.7
P/FCFE
P/FCFE
Price to FCFE
53.7
vs History
28
vs Industry
9
Median 3Y
35.8
Median 5Y
28.5
Industry
23.1
More Details
2.9
P/B
P/B
Price to Book Value
2.9
vs History
17
vs Industry
22
Median 3Y
1.8
Median 5Y
2.2
Industry
2
More Details
4.9
EV/S
EV/S
Enterprise Value to Sales
4.9
vs History
19
vs Industry
22
Median 3Y
3.4
Median 5Y
3.3
Industry
2.5
Forward
4.4
More Details
6.9
EV/GP
EV/GP
Enterprise Value to Gross Profit
6.9
vs History
20
vs Industry
27
Median 3Y
4.9
Median 5Y
4.6
Industry
4.8
More Details
20.4
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
20.4
vs History
20
vs Industry
16
Median 3Y
15.3
Median 5Y
13
Industry
12.5
Forward
14.5
More Details
35.9
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
35.9
vs History
31
vs Industry
10
Median 3Y
35.7
Median 5Y
17.5
Industry
15.7
Forward
21.7
More Details
24.5
EV/OCF
EV/OCF
Enterprise Value to OCF
24.5
vs History
25
vs Industry
15
Median 3Y
17.8
Median 5Y
16.2
Industry
14.1
More Details
33.1
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
33.1
vs History
26
vs Industry
13
Median 3Y
28.1
Median 5Y
24.9
Industry
17.6
More Details
2.4
EV/IC
EV/IC
Enterprise Value to IC
2.4
vs History
15
vs Industry
26
Median 3Y
1.5
Median 5Y
1.8
Industry
1.8
More Details

Multiples Across Competitors

UCB Competitors Multiples
Ucb SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
BE
Ucb SA
XBRU:UCB
29.3B EUR 4.7 27.1 20.4 35.9
US
Eli Lilly and Co
NYSE:LLY
707B USD 14.4 63.6 34.3 37.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
372.4B USD 4.2 17.1 12.5 16.4
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.8 19.5 12.9 14.7
CH
Roche Holding AG
SIX:ROG
204.9B CHF 3.4 24.8 9.3 10.9
CH
Novartis AG
SIX:NOVN
178.1B CHF 4 16.7 9.9 13.2
UK
AstraZeneca PLC
LSE:AZN
158.8B GBP 3.8 27.1 130.3 196.5
US
Merck & Co Inc
NYSE:MRK
194.2B USD 3 11.1 8 9.6
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
FR
Sanofi SA
PAR:SAN
116.5B EUR 1.3 9.2 5.1 5.9
P/E Multiple
Earnings Growth PEG
BE
Ucb SA
XBRU:UCB
Average P/E: 24
27.1
30%
0.9
US
Eli Lilly and Co
NYSE:LLY
63.6
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.1
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.5
18%
1.1
CH
Roche Holding AG
SIX:ROG
24.8
32%
0.8
CH
Novartis AG
SIX:NOVN
16.7
17%
1
UK
AstraZeneca PLC
LSE:AZN
27.1
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.1
18%
0.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
FR
Sanofi SA
PAR:SAN
9.2
28%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
BE
Ucb SA
XBRU:UCB
Average EV/EBITDA: 395.5
20.4
28%
0.7
US
Eli Lilly and Co
NYSE:LLY
34.3
31%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.5
8%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
12.9
14%
0.9
CH
Roche Holding AG
SIX:ROG
9.3
6%
1.6
CH
Novartis AG
SIX:NOVN
9.9
5%
2
UK
AstraZeneca PLC
LSE:AZN
130.3
9%
14.5
US
Merck & Co Inc
NYSE:MRK
8
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5.1
8%
0.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
BE
Ucb SA
XBRU:UCB
Average EV/EBIT: 1 699.8
35.9
44%
0.8
US
Eli Lilly and Co
NYSE:LLY
37.4
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.4
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
14.7
14%
1
CH
Roche Holding AG
SIX:ROG
10.9
6%
1.8
CH
Novartis AG
SIX:NOVN
13.2
10%
1.3
UK
AstraZeneca PLC
LSE:AZN
196.5
21%
9.4
US
Merck & Co Inc
NYSE:MRK
9.6
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5.9
14%
0.4

See Also

Summary
UCB intrinsic value, competitors valuation, and company profile.
DCF Valuation
UCB stock valuation using Discount Cash Flow valuation method.
Relative Valuation
UCB stock valuation using valuation multiples.
Wall Street Estimates
UCB price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
UCB stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 253,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.